@misc{10481/91001,
year = {2014},
month = {5},
url = {https://hdl.handle.net/10481/91001},
abstract = {Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen
for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase
inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects
without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to
adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The
primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to
suppress plasma HIV-RNA to ,50 copies/mL after 24 weeks on treatment, or a confirmed viral load .200 copies/mL in
patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty
seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9–92.1%) and 77.4% (CI95,
65.0–89.7%), respectively; the rates reached 97.2% (CI95, 95.1–99.3%) and 90.5% (CI95, 81.7–99.3), by on-treatment analysis.
The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1–2 adverse events were observed
motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable,
well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug
activity.},
publisher = {University of Rome Tor Vergata},
title = {Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population},
doi = {10.1371/journal.pone.0097262},
author = {López Cortes, LF and Viciana, Pompeyo and Girón González, José Antonio and Romero-Palacios, Alberto and Márquez Solero, Manuel and Martínez Pérez, María Ángeles and López Ruz, Miguel Ángel and De la Torre Lima, Javier and Delgado Fernández, Marcial and Gasrvía Lázaro, Milagros and Lozano, Fernando and Omar Mohamed-Balghata, Mohamed},
}